Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TKT | P29401 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1533803 | 1.00 | LMNA (0.53) | LMNATKTTDP1HSP90AA1 | |
| SCHEMBL479344 | 0.91 | LMNA (0.61) | LMNATKTHSP90AA1 | |
| Pyrophosphoric Acid SCHEMBL851327 | 0.91 | LMNA (0.51) | LMNATKTTDP1 | |
| SCHEMBL8445448 | 0.89 | LMNA (0.59) | LMNATKTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL6520994 | 0.89 | LMNA (0.59) | LMNATKTHSP90AA1 | |
| SCHEMBL849877 | 0.83 | LMNA (0.53) | LMNATKTTDP1 | |
| SCHEMBL3371360 | 0.79 | LMNA (0.61) | LMNATKTTDP1 | |
| SCHEMBL12346332 | 0.77 | LMNA (0.63) | LMNATKT | |
| SCHEMBL5916304 | 0.76 | LMNA (0.50) | LMNATKTTDP1 | |
| SCHEMBL851328 | 0.74 | LMNA (0.57) | LMNATKTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | PYRO PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | claimed |
| EP-2463654-B1 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | UNIV CALIFORNIA (US) | 2020-06-03 | — | — | EP | disclosed |
| US-8311790-B2 | Reverse engineering genome-scale metabolic network reconstructions for organisms with incomplete genome annotation and developing constraints using proton flux states and numerically-determined sub-systems | UNIVERSITY OF DELAWARE (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2463654-A1 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | The Regents of The University of California (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2434421-A2 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | The Regents of The University of California (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100280803-A1 | Compositions and Methods for Modeling Saccharomyces cerevisiae Metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-11-04 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090259451-A1 | REVERSE ENGINEERING GENOME-SCALE METABOLIC NETWORK RECONSTRUCTIONS FOR ORGANISMS WITH INCOMPLETE GENOME ANNOTATION AND DEVELOPING CONSTRAINTS USING PROTON FLUX STATES AND NUMERICALLY-DETERMINED SUB-SYSTEMS | UNIVERSITY OF DELAWARE (US) | 2009-10-15 | — | — | US | disclosed |
| US-20060252113-A1 | Methods for identifying compounds that modulate an enzyme in the glucose metabolic pathway of a pathogenic microorganism | SCHECHTER ALAN M | 2006-11-09 | — | — | US | disclosed |
| US-20060252112-A1 | Methods for indentifying compounds that modulate an enzyme involved in biotin metabolism in a pathogenic microorganism | SCHECHTER ALAN M | 2006-11-09 | — | — | US | disclosed |
| US-20060178322-A1 | Methods for indentifying compounds that modulate an enzyme involved in riboflavin metabolism in a pathogenic microorganism | SCHECHTER ALAN M | 2006-08-10 | — | — | US | disclosed |
| US-20060178320-A1 | Methods for indentifying compounds that modulate an enzyme involved in thiamine metabolism in a pathogenic microorganism | SCHECHTER ALAN M | 2006-08-10 | — | — | US | disclosed |
| US-20060178321-A1 | Methods for indentifying compounds that modulate an enzyme involved in reductive carboxylation in a pathogenic microorganism | SCHECHTER ALAN M | 2006-08-10 | — | — | US | disclosed |
| US-20060094075-A1 | Methods for indentifying compounds that modulate an enzyme in the coenzyme a biosynthetic pathway in a pathogenic microoganism | SCHECHTER ALAN M | 2006-05-04 | — | — | US | disclosed |
| US-20060063224-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway | SCHECHTER ALAN M | 2006-03-23 | — | — | US | disclosed |
| US-6955890-B2 | Method for the identification and treatment of pathogenic microorganisms infections by inhibiting one or more enzymes in an essential metabolic pathway | PYRO PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | PYRO PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030180830-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway | PYRO PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | disclosed |
| CN-1317051-A | HMP-P rinase and TMP-PPase from arabidopsis thaliana and their use in herbicide screening | SINGENPE AG (CH) | 2001-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252113-A1 | Methods for identifying compounds that modulate an enzyme in the glucose metabolic pathway of a pathogenic microorganism | MGAM, G6PD, UGDH | LMNA 3781/4885TKT 33/4885TDP1 3499/4885 |
| US-20060094075-A1 | Methods for indentifying compounds that modulate an enzyme in the coenzyme a biosynthetic pathway in a pathogenic microoganism | COASY, BPGM, ME1 | LMNA 3658/4885TKT 233/4885TDP1 3203/4885 |
| US-20060178320-A1 | Methods for indentifying compounds that modulate an enzyme involved in thiamine metabolism in a pathogenic microorganism | IMPDH1, SLC19A2, IMPDH2 | LMNA 2045/4885TKT 11/4885TDP1 2410/4885 |
| US-20060178322-A1 | Methods for indentifying compounds that modulate an enzyme involved in riboflavin metabolism in a pathogenic microorganism | BLVRB, IMPDH1, IMPDH2 | LMNA 2663/4885TKT 162/4885TDP1 3097/4885 |
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | CYP51A1, ME1, BPGM | LMNA 3872/4885TKT 24/4885TDP1 3936/4885 |
| US-20060252112-A1 | Methods for indentifying compounds that modulate an enzyme involved in biotin metabolism in a pathogenic microorganism | BTD, BLVRB, BPGM | LMNA 1995/4885TKT 133/4885TDP1 4162/4885 |
| US-20060178321-A1 | Methods for indentifying compounds that modulate an enzyme involved in reductive carboxylation in a pathogenic microorganism | CYP2E1, POR, BLVRB | LMNA 4306/4885TKT 344/4885TDP1 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.